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Based on extensive pre-clinical achievements over the past decades, it appears to be due time for a successful
clinical translation in the renal fibrosis field—but what is the quickest road to get there? In light of the recent
launch of the Precision Medicine Initiative and success of molecularly informed drugs in oncology, we here discuss
what it may take to bring molecularly targeted anti-fibrotic to clinical use in chronic progressive kidney disease.
Keywords: Fibrosis, Precision medicine, Epigenetics, Liquid biopsy, Clinical trialReview
Introduction
As the era of precision medicine begins to become real-
ity in oncology, “aiming to classify individuals into sub-
populations that differ in their susceptibility to a
particular disease, in the biology and/or prognosis of
those diseases they may develop, or in their response to
a specific treatment”, and to utilize such comprehensive
knowledge for molecularly informed therapies, there still
is no therapy available to inhibit fibrogenesis that under-
lies progression of chronic kidney disease as yet. With
regard to the recently proposed Precision Medicine Ini-
tiative in the USA with its two main components of “a
near-term focus on cancers and a longer-term aim to
generate knowledge applicable to the whole range of
health and diseases” (including chronic kidney disease
and fibrosis), we here review how modern cancer medi-
cine evolved and discuss how such knowledge gained in
the cancer field can be utilized to kick-start the era of
precision renal medicine and to implement molecularly
informed anti-fibrotics into clinical use.
Evolution from nitrogen mustard chemotherapy to
molecular targeted cancer therapy
The evolution of cancer therapies was kick-started by
initial studies by Gilman and Goodman linking nitrogen
mustard to regression of lymphoid tumors and clinical* Correspondence: mzeisberg@med.uni-goettingen.de
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oid leukemia upon administration of the folate antagonist
aminopterin [1–3]. While these initial chemotherapies
were considerably toxic, they served as proof-in-principle
for effective cancer therapies and eventually led to the
concept of potential cure of cancer [4]. For 50 years, rela-
tively unspecific and toxic substances, which primarily
aimed to kill actively dividing cells, remained the mainstay
of cancer therapies [5]. The new era of molecular targeted
therapies (use of drugs or other substances that block the
growth or spread of cancer by interfering with specific
molecules) started with approval of imatinib (Gleevec) for
clinical use in Philadelphia chromosome-carrier CML pa-
tients [6]. The Philadelphia chromosome refers to a recip-
rocal transclocation in which a region of chromosome 9
encoding for the Abl tyrosine kinase is fused to the BCR
(breakpoint-cluster-locus), resulting in a constitutively ac-
tive BCR-Abl tyrosine kinase fusion protein which ultim-
ately provides a constant proliferative signal in cancer cells
[6]. Imatinib is a tyrosine kinase specific inhibitor specific-
ally designed to fit the BCR-Abl ATP-binding site of the
protein created by the BCR-Abl translocation enabling for
the first time specific cancer therapy by targeting a causal
molecular target [7]. Today, there are already more than
75 FDA approved targeted cancer therapies, which are be-
ing used based on presence of respective targets within
malignant cells (http://www.cancer.gov). With still evolv-
ing molecular analytical tools and rapidly increasing num-
bers of target-specific drugs, the cancer field is currently
in flux: It is becoming increasingly obvious that cancers,
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into distinct subtypes due to their molecular signatures
[8–10]. Such molecular signatures can serve as basis
for individually stratified molecularly targeted therap-
ies, whereas traditional classifications were used to
stratify rather unspecific chemotherapies [8, 11]. Fur-
thermore, it is becoming evident that based on their
molecular signatures and disease drivers, tumor sub-
types of one organ origin differ substantially from an-
other but can be almost identical to tumor subtypes
from distant organs [12]. For example, bladder cancers
could be classified into subgroups, which remarkably
were almost indistinguishable from either lung adeno-
carcinomas or squamous cell cancers of the head and
neck [12]. These newly found molecular characteristics
have important implications for cancer therapies: For
example, in 60 % of melanoma patients, the B-Raf
proto-oncogene, serine/threonine kinase (BRAF) is mu-
tated [13]. Those patients respond to the BRAF inhibi-
tor vemurafenib; BRAF-negative patients do not [13].
However, patients with hairy cell leukemia with BRAF
mutations often also respond to vemurafenib therapy, ex-
emplifying applications of molecular diagnostics and tar-
geted therapies [14]. Overall, such “genomically informed
cancer therapies” are proving far superior over non-
targeted therapies and have prompted calls for reclassifica-
tion of cancers based on molecular profiles and targets
instead of being based on traditional histopathology and
origin—and opened the door for the Precision Medicine
Initiative [15].
As the cancer field is moving from histopathological
analysis to molecular profiling of cancer, not only trad-
itional histopathology-based tumor classifications are be-
ing challenged; the benefits of tumor biopsies per se is
also under scrutiny and analysis of cell-free DNA
(cfDNA) as “liquid biopsy” is increasingly being recog-
nized as complementation or even alternative to stand-
ard tumor biopsies [16]. Presence of fragmented cell-free
DNA in the blood long has been known [17]. Clinical
utilization of cfDNA was first adapted in pre-natal diag-
nostics, where fetus-derived cfDNA fragments within
maternal blood are used to determine gender and devel-
opmental disorders such as Down’s syndrome of the
fetus [18]. Studies from the cancer field established that
cfDNA obtained from blood represented all DNA modi-
fications present within primary tumors and metastases:
point mutations, rearrangements, amplifications, aneu-
ploidy, and DNA methylation [19]. With current tech-
nologies, sensitivity of cfDNA analysis is reaching almost
100 % and, due to accounting for tumor heterogeneity,
outperforms tumor biopsies with regard to molecular
profiling. Because blood sampling is minimally invasive,
analysis of cfDNA appears particularly primed for longi-
tudinal analysis of tumor burden and monitoring oftreatment response. In this regard, analysis of cfDNA
clearly outperformed protein biomarkers and imaging
techniques [19, 20]. Taken together, the cancer field has
evolved dramatically over the past two decades, opening
the door for precision medicine.
Obstacles and possible solutions for renal fibrosis
As compared to the cancer field, the one initiating clin-
ical study providing proof-in-principle that fibrosis can
be reversed in patients is still lacking. However, founded
on strong evidence from murine studies, the concept of
irreversibility of chronic kidney disease has given way to
increasing confidence that renal fibrosis is a treatable
target in principle and that possible regression of fibrosis
would translate into preservation of kidney function.
The new era of anti-fibrotics in the kidney was initiated
by the report of reversal of experimental chronic kidney
disease in 2003 [21]
. While several clinical trials to test efficacy of anti-
fibrotics in chronic kidney disease are currently under-
way [22], several obstacles need to be overcome to en-
able a precision anti-fibrotic renal medicine, possibly by
benefitting from the recent advances made in the cancer
field:
Possibilities for molecularly informed anti-fibrotic
therapies
Majority of current anti-fibrotic trials in chronic kidney
disease are not only done without molecular profiling of
enrolled patients; they are also done without kidney bi-
opsy (www.ClinicalTrials.gov). This can be mostly attrib-
uted to the fact that in patients with presumed diabetic
nephropathy and hypertensive nephrosclerosis, kidney
biopsy is not done for diagnostic purposes as diagnostic
insights do not outweigh procedural risks. In analogy to
the cancer field, clinical trials conceptually follow chemo-
therapy designs in the cancer field during the pre-
precision medicine area under the assumption that one
anti-fibrotic drug could be beneficial to all patients with
chronic kidney disease (the concept of “one-size-fits-all”
therapies). Notably, this is done with candidate com-
pounds which specifically target select molecular mecha-
nisms such as TGF-beta signaling, CTGF, or the
chemokine receptor 2, which were derived through mo-
lecular target identification and which fulfill requirements
for “molecularly informed targeted therapies”—only that
diagnostic molecular information of candidate patients are
not being assessed [22].
One reason for such strategy is likely the existing con-
cept of common kidney fibrosis pathways [23, 24]. Argu-
ments for such concept are obvious: Histopathological
studies revealed that the extent of tubulointerstitial fi-
brosis is the single best predictor of kidney function,
even in primary glomerular diseases [24, 25]. Because of
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form kidney fibrosis pathway underlying all chronic pro-
gressive nephropathies evolved [24, 26–34]. The concept
of a common fibrosis mechanism was further corrobo-
rated by overwhelming experimental evidence for a role of
transforming growth factor beta1 in renal fibrogenesis: In-
hibition of TGFβ-inhibited fibrosis in murine models
commonly used in kidney fibrosis research [35–38], TGFβ
was found to induce cellular events typically associated
with fibrosis in commonly used cell lines [39, 40], and
TGFβ was also implied as principal pro-fibrotic mediator
in other organs such as the skin, liver, and lung [41–43].
Based on this overwhelming body of evidence, TGFβ in-
hibition was identified as lead anti-fibrotic target and three
independent clinical trials with TGFβ inhibitors have been
initiated in the kidney (for review see). However, proof of
envisioned efficacy is still lacking (Dr. James Voelker of Eli
Lilly and Co. reported at the ASN Kidney Week 2014
that anti-TGFβ1 therapy in patients with advanced dia-
betic nephropathy with a humanized anti-TGFβ1 anti-
body LY2382770 in a phase II dose-ranging study was
terminated early due to efficacy futility [22]).
In hindsight, this may not be surprising. As TGFβ was
identified as a major mediator of common kidney fibro-
sis pathways, controlled clinical studies which analyzed
utility of circulating or urinary TGFβ as biomarker for
chronic progressive kidney disease did not reveal a prog-
nostic value [44, 45]. Retrospectively, this may have been
due to the fact that there are patients in which TGFβ is
not involved—simply put that kidney fibrosis pathways
are less common than previously thought. In this regard,
a previous study reported that experimental renal fibro-
sis also occurs when TGFβ signaling is inactive (due to
lack of thrombospondin)—it just takes longer to evolve
[46]. Importantly, such TGFβ-independent tubulointer-
stitial fibrosis differed in cellular and extracellular com-
position—even though such differences were not
detected by standard histopathological analysis of the
relative interstitial volume [46].
Cancer biology taught three principal aspects: That
among cancers which are being grouped as one entity
according to established classifications, subgroups exist
which can be classified according to their underlying
oncogenic pathways, that these oncogenic pathways are
disease drivers within cancers of different entities at dif-
ferent organs, and that with regard to molecularly in-
formed targeted therapies the molecular signatures are
more relevant than traditional classifications. In analogy,
recent evidence regarding renal fibrogenesis is suggest-
ing that there are distinct fibrotic pathways which
underlie progression of chronic kidney disease (and that
these pathways could serve as basis for classification of
chronic kidney disease for molecularly informed therap-
ies). Furthermore, evidence is also suggesting that thesepathways (i.e., TGFβ signaling) are disease drivers in
subtypes of fibrosis across all organs. One should not
take the second step before the first step: As molecularly
targeted anti-fibrotics are available, it appears reasonable
to use them in a molecularly informed fashion and to
implement molecular profiling into clinical diagnostics
and clinical-trial designs.
Attraction of a liquid renal biopsy
While kidney tissue is the gold standard for clinical diag-
nosis and investigational sequencing, kidney biopsies are
associated with several limitations per se. Percutaneous
kidney biopsies are not only an inconvenient, cost-
intensive procedure; they often are without impact on
clinical outcome (i.e., in context of diabetic nephropathy,
hypertensive nephrosclerosis, or acute kidney injury), they
are also not without clinical complications (main compli-
cations are gross hematuria, transfusion-requiring bleed-
ing, abcesses, and urosepsis and occur at rates between 2
and 4 % in the literature). Furthermore, standard tech-
niques (formalin-fixation and paraffin-embedding) used
for histopathological analysis impair current sequencing
technologies through DNA crosslinking. Also, tissue het-
erogeneity is a major limitation of kidney biopsies, as
tubulointerstitial fibrosis (and subsequently DNA-, RNA-,
and protein-modifications) is not evenly distributed within
the diseased kidney and common biopsy-cores are often
not representative. To overcome these limitations, less in-
vasive diagnostic tests which most importantly reflect tis-
sue heterogeneity would be highly desirable.
Despite convincing utility of cfDNA analysis for cancer
diagnostics, there are obvious limitations to translate such
technology to renal medicine: Based on current knowledge,
there are no obvious point mutations, rearrangements, am-
plifications, or aneuploidy involved in progression of renal
fibrogenesis. As large cohorts studies to identify genetic
polymorphisms which are directly linked to susceptibility
for fibrosis progression are underway [47–49], it is clear
that even if such traits will be identified, they will not lend
themselves for monitoring of disease progression or treat-
ment responses (based on current knowledge, fibrogenesis
is not associated with acquisition of de novo somatic muta-
tions or polymorphisms and hence do not lend themselves
for longitudinal analysis—unlike in cancer where genetic in-
stability and de novo mutations are a hallmark of cancer
progression).
Recent studies suggest that these limitations can be
overcome by analysis of epigenetic marks, because epi-
genetics in general offer the advantage of greater stability
over mRNA or protein-based biomarkers (which are
more dynamic and subject to greater fluctuation, often
providing a snap-shop at time of analysis over a long-
term picture which underlies individual progression of
kidney fibrosis) but do underlie modifications during
Zeisberg and Zeisberg Fibrogenesis & Tissue Repair  (2015) 8:16 Page4of6disease progression or treatment responses as opposed
to genetics [50, 51]. While major epigenetic mechan-
isms—CpG promoter methylation, histone modifications,
and micro RNAs—interact and impact each other, analysis
of DNA methylation offers the advantage of being gene
target specific by definition, whereas histone modifications
and micro RNAs target numerous genes, requiring further
complex analyses (if a specific gene promoter is methyl-
ated, as possibly detected by methylation-specific PCR,
this means that transcription of this specific genes is si-
lenced) [50, 52]. Altered presence of single microRNA
causes altered expression of numerous genes, typically re-
quiring additional transcriptional profiling to assess con-
text dependent relevance [53]. Histone modifications are
most complex, as those occur at multiple sites within mul-
tiple genes, blurring assessment of biological impact of
identified modification [54]. In this regard, in context of
kidney fibrosis several methylation marks with direct
causal consequence to renal fibrogenesis have been identi-
fied, similar to what has been revealed by analysis of
monozygous twins in the cancer field [50, 55–57]. What is
even more appealing is that levels of circulating methyl-
ated DNA promoter fragments reflect intrarenal levels of
methylated promoter CpG islands of respective genes,
providing a cue for a liquid renal biopsy in the future [50].
For example, our group identified that CpG promoter
methylation of RASAL1 (which encodes for an endogen-
ous Ras-GTP inhibitor) causes transcriptional silencing of
this gene and contributes causally to progression of renal
fibrogenesis [58]. We also identified that levels of RASAL1
CpG island promoter methylation correlates with extent
of tubulointerstitial fibrosis in renal biopsies and with GFR
decline [40]. Finally, we reported that levels of circulating
methylated DNA promoter fragments reflect intrarenal
levels of methylated promoter CpG islands of RASAL1
and also correlated with successful de-methylating therap-
ies in mice [50]. While more work needs to be done to
identify disease relevant threshholds of RASAL1 methyla-
tion, the use RASAL1-methylation stratified use of Ras-
GTP inhibitors could serve as one example of how a n
epigenetic biomarker-informed molecular therapy could
be envisioned (just like methylated fragments of TGF-β
and its receptors could be taken as strong indication not
to use TGF-β inhibitors).
Conclusions
Based on extensive pre-clinical achievements over past
decades it appears to be due time for successful clinical
translation in the renal fibrosis field—but what is the
quickest road to get there? With the bar being set high
by the US Food and Drug Administration (the FDA cur-
rently accepts halving of glomerular filtration rate
(GFR)—and in certain circumstances 40 % over 2–
3 years, as a surrogate end point clinical trials of CKDprogression [59]), it may be time well-spent to re-think
current clinical trial strategies to increase likelihood of
success (and to avoid costly avoidable failures). Based on
the substantial advances made in the cancer field, which
culminated in molecularly informed therapeutics and
launch of the precision medicine area, we believe that it
may be wise to learn from the growing pains of oncology
and utilize such experience for renal fibrosis trial design.
In this regard, there seems to be a mismatch between
the specific molecularly targeted anti-fibrotics which are
being tested and the relatively uninformed trial designs
which are being used.
Per current thinking, patients diagnosed with diabetic
nephropathy and or hypertensive nephrosclerosis or
FSGS at CKD stages 2–3 are regarded as attractive study
population, because such patients promise rapid-enough
disease progression to obtain results with relatively short
observation time (2–3 years), and because they are com-
mon enough to recruit sufficient patient numbers for ad-
equately powered trials (based on standard metrics).
Obvious drawback of such design is that patients mostly
do not undergo kidney biopsy at study entry (especially
in case of diabetic nephropathy and nephrosclerosis) and
that there is no knowledge if the targeted disease mech-
anism is even active. Bluntly putwith the example of
TGF-β inhibition: when TGF-β signaling is not active,
TGF-β inhibition cannot work. In other words in ana-
logy to the cancer field—current renal fibrosis trials fol-
low the trial design of when nitrogen mustard was used,
neglecting possibilities of molecular stratification. It just
seems plausible that the likelihood of therapeutic success
is higher when the molecular target of a moleculalry tar-
geted therapy is active in a respective patient and that it
would be of benefit to enrich such patients in a study
cohort by analyzing such targeted pathway at the time of
patient recruitment.
One reason for such neglect might be the concept of a
uniform fibrosis pathway, which conceptually justifies
aforementioned “one-size-fits-all” therapeutic strategies.
The promise of a common pathway which drives fibrosis
in all organs (and thus causally contributes to 30 % of
mortality world-wide) has obvious charms; but evidence
is increasing that this may have been an over-simplified
view. While such concept enhanced interaction of fibro-
sis research across all disciplines, these interactions re-
vealed that fibrosis across organs is similar, albeit with
different flavors and nuances [60]. And similarly, it ap-
pears plausible that—while mechanisms of fibrosis are
similar in individual patients, there may be differences
which pathway is the causal driver in such patients. Dif-
ficulties to establish known pro-fibrotic mediators (such
as TGF-β) reliable biomarkers of CKD, point towards
such thinking. Again in analogy to advances in the can-
cer field disease, progression in a patient with diabetic
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more similar to a patient with interstitial nephrits and
high TGF-β levels as compared to a patient with diabetic
nephropathy and low TGF-β expression. And in further
analogy, it appears plausible that the fibrosis in patients
with interstitial nephritis and high eosionophiluria is
more similar to the fibrosis in patients with idiopathic
pulmonary fibrosis and high eosinophil count within
bronchial fluid than to the fibrotic process in patients
with hypertensive nephrosclerosis, particularly from a
therapeutic point of view. Introduction of CKD grading
and staging criteria may have been a first step towards a
molecular pathway-based classification, and in this re-
gard emerging big data should be utilized to identify
specific subsets of patients (as opposed to solely focusing
on common denominators) and we believe that analysis
of epigenetic modifications in fluids such as blood and
urine may have the highest utility to identify such pa-
tient subsets. While the concept of a personalized medi-
cine has been known for a while, launch of the Precision
Medicine Initiative and obvious difficulties to translate
pre-clinical advances to clinical practice in nephrology
should serve as exclamation marks to nudge the renal fi-
brosis field to finally adopt such thinking.
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